Biotech as a Service
Accelerate your early Drug Development
A ready‑to‑run drug development engine
for early oncology and immunology assets
We provide integrated, hands‑on development leadership across CMC, preclinical, regulatory, clinical and operations - allowing your organization to move faster, with less execution risk, without building a full in‑house organization.
The execution gap in early drug development
Early drug development rarely fails because of science alone. It fails because execution is fragmented.
And this is something you can easily fix.
Early‑stage biotechs and spin‑outs face the same structural challenges:
-
Limited internal resources
-
Gaps in senior cross‑functional leadership
-
Complex coordination across CDMOs and CROs
-
High pressure to reach value‑defining inflection points fast
Building a full development organization too early is costly and slow. Outsourcing without ownership creates risk.
Billions of R&D capital are lost due to fragmented
early-development capabilities
20% of assets successfully move to Proof of Concept
Our solution: a plug‑in development engine
We act as your embedded drug development organization:
your bring the asset, we move it forward.
You plug your asset into a fully integrated and agile execution team that covers:
-
CMC & Manufacturing
-
Preclinical & Translational Development
-
Regulatory strategy & CTA‑enabling packages
-
Clinical development to Proof of Concept
-
Quality Assurance & GxP compliance
-
Program leadership, vendor governance and operations
One team. One vision. One accountable partner.
Why choose us?
We are not a CRO - We are a Biotech at heart
-
Hands‑on, senior leadership: We lead and deliver, focused on company goals
-
End‑to‑end ownership: From early development decisions to PoC
-
Standardized playbook: Proven execution model that reduces timelines
and operational risk -
Pharma‑grade execution: Speed without sacrificing rigor
